Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
CJC-1295 (DAC) GHRH analog. Stimulates pituitary GH release, elevates hepatic IGF-1 production, activates mTOR signaling 6–8 days 100mcg 2x/week subcutaneous Serum IGF-1 AUC, lean body mass (DEXA), muscle CSA (MRI) Gold standard …
GHK-Cu ECM remodeling, VEGF upregulation Lysyl oxidase, TGF-β pathway 0.05–0.2% topical daily 30 days (2–8°C, light-protected) Phase II clinical data; 285% follicle enlargement in vitro TB-500 Anti-inflammatory, stem cell migrati…
GHK-Cu (Copper Peptide) Upregulates collagen I/III synthesis via TGF-β signaling; modulates MMP-1/2 activity to reduce collagen degradation Microneedling (0.5–1.5mm depth) with 0.05–0.1% solution applied immediately post-treatmen…
Kisspeptin-10 GPR54 agonist. Triggers GnRH neuron activation 0.3–9.6 nmol/kg IV 28 minutes −20°C lyophilized; 2–8°C reconstituted (use within 7 days) Most precise tool for studying acute GnRH release. Short half-life means tempor…
Conventional anti-inflammatory protocols (NSAIDs, corticosteroid injections) suppress cyclooxygenase enzymes and reduce prostaglandin production, which lowers pain signaling but also blunts the inflammatory phase that's required …
DSIP Modulates thalamic delta wave generation via calcium channel stabilization Stage 3 slow-wave sleep 20–40 minutes post-administration Most direct sleep-inducing mechanism. Increases slow-wave sleep without REM suppression or …
BPC-157 VEGF upregulation, fibroblast migration Strong. Promotes neovascularization in hypovascular tendon tissue Moderate. Indirect via improved blood supply 250–500 mcg/day Daily subcutaneous Best first-line choice for chronic …
BPC-157 Upregulates occludin and ZO-1 via VEGF/FAK pathways 10 mcg/kg daily (animal models) None published for permeability 10–14 days (rodent models) Strongest preclinical evidence for tight junction protein synthesis; reproduci…
CJC-1295 GHRH analog. Extends GH pulse duration Lean mass preservation, sleep quality improvement 1–2mg subcutaneous weekly 52-week trial: 92% lean mass retention vs 78% control Gold standard for GH axis restoration without recep…
Before selecting a peptide, clarify the pathophysiological model you're investigating. Central vs peripheral, hormonal vs neurovascular, acute vs chronic. PT-141 (bremelanotide) Melanocortin-4 receptor agonist. Central dopaminerg…
Semax Increases dopamine/norepinephrine turnover via BDNF-mediated tyrosine hydroxylase upregulation Intranasal 0.1–0.3% solution, 2–3 drops per nostril twice daily 7–14 days for measurable attentional improvements Best-suited fo…
BPC-157 VEGF receptor upregulation, blood-joint barrier stabilisation Cartilage degradation, tendon injury, synovial inflammation 68% reduction in synovial inflammation markers (rat CIA model, Frontiers in Immunology 2023) ≥98% p…
DSIP GABA-A positive allosteric modulation VLPO activation in hypothalamus +31% delta-wave power (NREM stage 3) Limited human trial (n=18) Delta-wave enhancement models Epithalon Circadian clock gene upregulation BMAL1, PER2, CRY…
Palmitoyl Pentapeptide-4 (Matrixyl) Signals fibroblasts to increase collagen I/III and elastin synthesis 117% increase in collagen I synthesis, 23% wrinkle reduction at 12 weeks (Int J Cosmet Sci) 3–5% 8–12 weeks Requires consist…
Orexin-A OX1R, OX2R (orexin receptors) Stabilises wake during work periods; no phase shift Neutral. Does not suppress REM or SWS 50–100mcg intranasal at shift start Best for excessive sleepiness during night shifts. Addresses wak…
BPC-157 Upregulates GH receptors, increases VEGF and collagen Type I synthesis via FAK-paxillin pathway Proliferation (7–21 days) Increased breaking force, accelerated tendon-to-bone healing, improved vascularization Daily (200–5…
Kisspeptin-10 Direct GnRH neuron activation via GPR54 Immediate LH pulse restoration None. Bypasses metabolic signaling Human trials in HA populations (JCEM 2014) Diagnostic tool; restores pulsatility temporarily but does not add…
TB-500 (Thymosin Beta-4) Upregulates Tregs; reduces CD8+ T-cell infiltration; promotes actin-mediated tissue repair Subcutaneous injection, 2–5mg twice weekly 60% reduction in CD8+ infiltration (animal model); anagen follicle res…
Before selecting a peptide, understand which memory pathway is impaired. Cholinergic deficiency presents differently than neurotrophic insufficiency or mitochondrial dysfunction. And the compounds that address each are mechanisti…
BPC-157 Angiogenesis via VEGF upregulation VEGFR-2 activation in endothelial cells 4–6 hours 10 mcg/kg daily, local injection 8–12 weeks at 2–8°C Best for acute injuries where vascular repair is the primary bottleneck. Builds new…